Preclinical toxicological study of phosphonoacetic acid: determination in blood by selected ion monitoring.
Confirmed observations of the inhibition of oncogenic viruses by phosphonoacetic acid led to preclinical trials in animal model systems. Circulating phosphonoacetic acid was detected in the blood of mouse, rabbit and monkey after oral or subcutaneous administration of the drug. Phosphonoacetic acid is quantified in blood, after removing proteins and lipids, as the trimethylsilylated derivative, by monitoring the intensity of the protonated molecular ion and also that of phosphonopropionic acid (internal standard) using chemical ionization mass spectrometry combined with gas chromatography. The detection limit is 20 ng ml-1 when 0.2 ml serum is analyzed. A dosage of 230 mg kg-1 day-1 by continuous infusion is proposed for therapeutic trials in monkeys. This dose is well tolerated and results in slowly increasing blood levels of phosphonoacetic acid which reach a maximum of approximately 50 microgram ml-1 in a four day infusion, and decrease to 2 microgram ml-1 24 h after termination.
D000818:Animals; D002849:Chromatography, Gas / Q000379:methods; D000882:Haplorhini; D013058:Mass Spectrometry / Q000379:methods; D051379:Mice; D008832:Microchemistry; D009943:Organophosphorus Compounds / Q000097:blood*; D010746:Phosphonoacetic Acid / Q000097:blood*; D011817:Rabbits; D012453:Saimiri; D013045:Species Specificity
D009943:Organophosphorus Compounds; D010746:Phosphonoacetic Acid